On Jul. 26, 2021, Trevena announced that the first COVID-19 patient had been enrolled in the NIH-funded ACTIV-4 Host Tissue (Accelerating COVID-19 Therapeutic Interventions and Vaccines) trial.

The trial, known as ACTIV-4 Host Tissue, tested four investigational agents that combat dysregulation of the renin-angiotensin-aldosterone system (RAAS) and the immune system caused by a COVID-19 infection.